Conclusions
cessation failure, tobacco-related disease
In this randomized clinical trial of adapted pharmacotherapy vs standard of care pharmacotherapy, adaptation to varenicline and/or bupropion + NP after failure of NP monotherapy did not significantly improve abstinence rates for Black adults who smoke relative to continued treatment with NP. However, these findings suggest that those who responded to pharmacotherapy in the first 2 weeks of the study had a 5 times greater odds of being abstinent at week 12. Findings highlight the continued need to identify effective treatment, particularly for those at high risk for cessation failure and those disproportionately impacted by tobacco-related disease.